We are live on ! Find out more
ICM

Invenomic Capital Management Portfolio holdings

AUM $2.18B
1-Year Est. Return 0.03%
This Fund
S&P 500
This Quarter Est. Return
-6.53%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$31.1M
Cap. Flow
+$160M
Cap. Flow %
7.34%
Top 10 Hldgs %
25.32%
Holding
187
New
40
Increased
44
Reduced
62
Closed
37

Top Buys

Rank Stock Value
1
WDAY icon
Workday
WDAY
+$88.9M
2
HAE icon
Haemonetics
HAE
+$43.3M
3
FIS icon
Fidelity National Information Services
FIS
+$41.7M
4
UHS icon
Universal Health Services
UHS
+$38M
5
CRM icon
Salesforce
CRM
+$37.1M

Top Sells

Rank Stock Value
1
EQX icon
Equinox Gold
EQX
+$42.5M
2
ACHC icon
Acadia Healthcare
ACHC
+$38.6M
3
CNXC icon
Concentrix
CNXC
+$36.4M
4
VTRS icon
Viatris
VTRS
+$33.1M
5
MTB icon
M&T Bank
MTB
+$31.3M

Sector Composition

Rank Sector Weight
1 Technology 30.56%
2 Healthcare 19.11%
3 Consumer Discretionary 12.35%
4 Industrials 11.07%
5 Consumer Staples 7.77%

No holdings matched the selected filter criteria.

4 5 6 7 8

Similar funds

SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
ORCP
One Rock Capital Partners New York $2.19B AUM
ET
Entropy Technologies New York $2.17B AUM 21.46% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
MIAS
Mason Investment Advisory Services Reston, Virginia $2.17B AUM 28.39% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
IIP
Intermede Investment Partners London, United Kingdom $2.16B AUM 18.47% 1-Year Est. Return

Invenomic Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Invenomic Capital Management held 187 positions worth $2.18B, up 1.4% from $2.15B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Invenomic Capital Management deployed $160M of net new capital in Q1 2026, opening 40 new positions and adding to 44 existing holdings. Its largest new stake was Workday: 559,955 shares worth $72.7M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Acadia Healthcare, an estimated $38.6M trimmed.

  • Invenomic Capital Management's largest Q1 2026 buy was Workday: 559,955 shares worth $72.7M.
  • Invenomic Capital Management added most to Fidelity National Information Services in Q1 2026, an estimated $41.7M increase.
  • Invenomic Capital Management's biggest Q1 2026 reduction was Acadia Healthcare, cutting an estimated $38.6M.
  • Invenomic Capital Management fully exited Equinox Gold in Q1 2026, selling an estimated $42.5M.
  • Invenomic Capital Management's ten largest holdings make up 25% of its $2.18B portfolio in Q1 2026.
  • Invenomic Capital Management opened 40 new positions and closed 37 in Q1 2026.
  • Invenomic Capital Management's portfolio value rose 1.4% quarter-over-quarter to $2.18B.

Based on Invenomic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.